JAMA internal medicine TAKE-HOME MESSAGE Researchers retrospectively evaluated 754 patients with healthcare-associated Clostridium difficile infection to determine the association of proton pump inhibitor use (PPI) with recurrence. The hazard ratio for recurrence was 1.5 for continuous PPI use, and 47.1% of patients receiving PPIs had an evidence-based indication. Researchers suggest that PPI use without proper […]
Circulation, 08/20/2013 Exclusive Author Commentary Clinical Article Ghebremariam YT et al. – Proton pump inhibitors (PPIs) are gastric acid–suppressing agents widely prescribed for the treatment of gastroesophageal reflux disease. Recently, several studies in patients with acute coronary syndrome have raised the concern that use of PPIs in these patients may increase their risk of major […]
Published: Apr 30, 2014 By Elbert Chu The FDA failed to respond to a 2011 petition demanding strong warnings about proton pump inhibitors (PPIs), according to a Public Citizen’s lawsuit filed today. Public Citizen’s lawsuit seeks a ruling from the U.S. District Court of the District of Columbia that the FDA unlawfully withheld action, and calls for an […]
PPIs, Mortality, and Rehospitalization in Older Patients Post Hospitalization RESEARCH · April 01, 2013 TAKE-HOME MESSAGE Use of proton pump inhibitors (PPIs) is associated with an increased risk of all-cause mortality in older patients discharged from acute care hospitals, even after adjusting for established predictors of adverse outcomes in this population, for whom physicians need […]
Published: Dec 11, 2013 By Cole Petrochko, Staff Writer, MedPage Today Full Story: http://www.medpagetoday.com/Endocrinology/GeneralEndocrinology/43363 Vitamin B12 deficiency is significantly more likely among patients taking prescription medications for gastroesophageal reflux disease (GERD), researchers found. Taking either a proton pump inhibitor or a histamine 2 receptor antagonist over 2 years was associated with a greater risk for […]
DISSECTING THE EVIDENCE David A. Johnson, Edward C. Oldfield IVDisclosures Clin Gastroenterol Hepatol. 2013;11(5):458-464. INTRODUCTION Proton pump inhibitors (PPIs) are medications that are ubiquitous in a gastroenterologist’s practice. This class of medication has been available for commercial use for nearly 25 years and this class of acid-reduction agents has supplanted the use of histamine-2–receptor antagonists […]
Mark Crane May 10, 2013 The acid blocker esomeprazole (Nexium, AstraZeneca) and the antipsychotic medication aripiprazole (Abilify, Otsuka Pharmaceutical Co) are the top-selling US prescription drugs for the first quarter of this year, according to a recent report from Drugs.com, an online drug information resource. The 2 drugs, with quarterly sales in the $1.5 billion range, rank […]